Skip to Content

    Celltrion specializes in “bio­similars”—cheaper generic versions of the pricey “biologic” drugs that are among Big Pharma’s bestsellers. Wall Street analysts project that the firm could achieve up to 25% future annual growth, with sales in multiple markets. U.S. regulators approved this country’s first ­biosimilar in 2015. Since then, Celltrion and its partners have won FDA approval for copies of Johnson & Johnson’s anti-­inflammatory treatment ­Remicade. And in early October, the team got an important preliminary thumbs-up from an FDA advisory panel for a biosimilar version of Roche’s blockbuster cancer drug Rituxan.

    41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

    Company Information

    Overall Score3.6
    Sector
    Health Care
    Industry
    Biotechnology
    CEO
    Woo-Sung Kee
    Websitehttp://www.celltrion.com
    Employees1,218
    HQ Location
    Incheon, South Korea
    Revenues ($M) (Past 12 Months)$925
    Profits ($M) (Past 12 Months)$351
    Market Value as of Oct. 10, 2018 ($M)$31,360